Ovarian Cancer: Examining the Microenvironment and Mutational Landscapes to Tailor Treatments

The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held this year at the Hynes Convention Center in Boston Oct. 26-30, has once again brought together members of academia, pharmaceutical industry, federal regulatory agencies, and all other stakeholders in the cancer drug development space from across the globe to discuss the most up-to-date advances.

A couple of studies presented at the conference set out to address an important question in cancer research – why is ovarian cancer so hard to treat?

Read More

FDA Approves Ovarian Cancer Treatment Based on New Biomarker

On Wednesday, the U.S. Food and Drug Administration (FDA) expanded the use of the molecularly targeted therapeutic niraparib (Zejula) to include an additional group of patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: those whose cancer has progressed despite treatment with at least three different cytotoxic chemotherapy regimens and tests positive for a new biomarker called homologous recombination deficiency (HRD).

Read More

Addressing Ovarian Cancer’s Unique Challenges

September is Ovarian Cancer Awareness Month. It’s an apt time for the American Association for Cancer Research (AACR) Advances in Ovarian Cancer Meeting, scheduled for Sept. 13-16 in Atlanta.

Ovarian cancer is a fairly rare cancer, accounting for only 1.3 percent of new cancer diagnoses in 2019. However, it is a deadly cancer, with only 47.6 percent of patients surviving for five years or longer. Because there are no good diagnostic tests for ovarian cancer, most patients are diagnosed at an advanced stage, when the disease is difficult to treat.

Read More

Examining the Tumor Microenvironment and Metabolism in Ovarian Cancer

Dong-Joo (Ellen) Cheon, PhD, Assistant Professor of Regenerative and Cancer Cell Biology at Albany Medical College and the 2017 AACR Gertrude B. Elion Cancer Research Award grantee, has been working in the field of ovarian cancer her entire career.

She was first introduced to ovarian cancer research as a graduate student at The University of Texas Health Science Center at Houston when she was tasked with generating CA125 knockout mice. CA125, or cancer antigen 125, is a blood serum biomarker routinely used to diagnose and monitor ovarian cancer.

Read More

Q&A with Anil K. Sood, MD, on Ovarian Cancer Research and Treatment

On Sunday, almost 300 of the greatest minds in ovarian cancer research will come together in Pittsburgh to discuss the latest advances in the field at the American Association for Cancer Research four-day conference on Addressing Critical Questions in Ovarian Cancer Research and Treatment.

Read More

FDA Approves New PARP Inhibitor for Ovarian Cancer

Earlier this week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers that are responding to platinum-based chemotherapy.

Read More